moleculin biotech, INC. (NASDAQ:MBRX) Files An 8-K Results of Operations and Financial Condition
Item 2.02.
|
Results of Operations and Financial Condition. |
On May 23, 2017, Moleculin Biotech, Inc. issued a press release
announcing that it had issued a business update letter to its
shareholders. A copy of the press release, which includes the
letter, is attached to this report as Exhibit 99.1 and is
incorporated by reference herein.
In accordance with General Instruction B.2. of Form 8-K, the
information in this Current Report on Form 8-K, including Exhibit
99.1, shall not be deemed to be filed for purpose of Section 18
of the Securities and Exchange Act of 1934, as amended (the
Exchange Act), or otherwise subject to the liabilities of that
section, and shall not be deemed incorporated by reference into
any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference
in such a filing.
| Item 9.01 | Financial Statements and Exhibits. |
(d)Exhibits.
| Exhibit No. | Description |
| 99.1 | Moleculin Biotech, Inc. press release dated May 23, 2017 |
About moleculin biotech, INC. (NASDAQ:MBRX)
Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). Annamycin is a Phase II clinical-stage anthracycline and liposome formulated anthracycline that has been designed to eliminate cardiotoxicity and avoid the multidrug resistance mechanisms. It has over two other drug development projects in progress, one involving a portfolio of small molecules, which it refers to as the WP1066 Portfolio, focused on the modulation of key oncogenic transcription factors involved in the progression of cancer, and the WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer in general, and glioblastoma. As of September 30, 2016, it had not generated any revenue from its operations. moleculin biotech, INC. (NASDAQ:MBRX) Recent Trading Information
moleculin biotech, INC. (NASDAQ:MBRX) closed its last trading session up +0.099 at 0.869 with 68,762 shares trading hands.
